The FDA is now requiring a black box warning for etanercept (ENBREL), a drug for rheumatoid arthritis, manufactured by Immunex Corporation and marketed by Angen and Wyeth pharmaceuticals. The black box warning will be added to the drug’s label. Etanercept is the brand name with ENBREL being the generic name. However, the drug is not yet available in generic form. The warning concerns rare – but possible – tuberculosis infections. Etanercept is an effective disease-modifying anti-rheumatic drug with annual sales of $875 million in 2007. The warning says that persons should undergo TB testing before starting the drug.
Source: Public Citizen
Contact us today for a free legal consultation with an experienced attorney.
Fields marked *may be required for submission.
If you would like to subscribe to the Jere Beasley Report digital edition, simply visit our Subscriptions page and provide the necessary information or call us at 800-898-2034.
Attorney Advertising - Prior results do not guarantee a similar outcome.